연구성과로 돌아가기
2022 연구자 정보 (72 / 1074)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Tokunaga, Eriko (Tokunaga, E) |
Natl Hosp Org, Kyushu Canc Ctr, Fukuoka, Japan |
|
|
[JCR상위 2.7] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. [JCR상위 0.9] Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer |
SCIE | 0.9 |
ONCOLOGY MEDICINE, GENERAL & INTERNAL |
modis@mskcc.org; | ||
|
Tsurutani, Junji (Tsurutani, J) |
Showa Univ Hosp, Tokyo, Japan |
|
|
[JCR상위 2.7] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. [JCR상위 0.9] Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer |
SCIE | 0.9 |
ONCOLOGY MEDICINE, GENERAL & INTERNAL |
modis@mskcc.org; | ||
|
Ueno, Naoto T. (Ueno, NT) |
Univ Texas MD, Anderson Canc Ctr, Houston, TX USA |
|
0000-0002-0166-7275 Ueno, Naoto |
[JCR상위 2.7] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. [JCR상위 0.9] Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer |
SCIE | 0.9 |
ONCOLOGY MEDICINE, GENERAL & INTERNAL |
modis@mskcc.org; | ||
|
Vidal, Maria (Vidal, M) |
Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain |
AAJ-8633-2021 Losada, Maria |
0000-0003-1992-5727 Vidal Losada, Maria |
[JCR상위 2.7] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. [JCR상위 0.9] Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer |
SCIE | 0.9 |
ONCOLOGY MEDICINE, GENERAL & INTERNAL |
modis@mskcc.org; | ||
|
Wang, Xiaojia (Wang, XJ) |
Zhejiang Canc Hosp, Hangzhou, Peoples R China |
|
|
[JCR상위 2.7] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. [JCR상위 0.9] Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer |
SCIE | 0.9 |
ONCOLOGY MEDICINE, GENERAL & INTERNAL |
modis@mskcc.org; | ||
|
Wang, Yibin (Wang, YB) |
Daiichi Sankyo, Basking Ridge, NJ USA |
|
|
[JCR상위 2.7] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. [JCR상위 0.9] Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer |
SCIE | 0.9 |
ONCOLOGY MEDICINE, GENERAL & INTERNAL |
modis@mskcc.org; | ||
|
Watras, Magdalena (Watras, M) |
|
|
[JCR상위 2.7] Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from the phase 2 study 22 (NCT02519348) | SCIE | 2.7 | ONCOLOGY | ||||
|
Whitcomb, David C. (Whitcomb, DC) |
Ariel Precis Med, Pittsburgh, PA USA Univ Pittsburgh, Dept Med, Pittsburgh, PA USA Univ Pittsburgh, Dept Cell Biol & Mol Physiol, Pittsburgh, PA USA Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA USA |
|
|
[JCR상위 2.7] Estrogen-Related Receptor γ Maintains Pancreatic Acinar Cell Function and Identity by Regulating Cellular Metabolism | SCIE | 2.7 | GASTROENTEROLOGY & HEPATOLOGY | eiji.yoshihara@lundquist.org;evans@salk.edu;jmsuh@kaist.ac.kr; | ||
|
Xu, Binghe (Xu, BH) |
Chinese Acad Med Sci, Canc Hosp, Peking Union Med Coll, Beijing, Peoples R China |
|
|
[JCR상위 2.7] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. [JCR상위 0.9] Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer |
SCIE | 0.9 |
ONCOLOGY MEDICINE, GENERAL & INTERNAL |
modis@mskcc.org; | ||
|
Yamashita, Toshinari (Yamashita, T) |
Kanagawa Canc Ctr, Yokohama, Japan |
GZN-0536-2022 Yamashita, Toshinari |
0000-0002-6479-1660 Yamashita, Toshinari |
[JCR상위 2.7] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. [JCR상위 0.9] Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer |
SCIE | 0.9 |
ONCOLOGY MEDICINE, GENERAL & INTERNAL |
modis@mskcc.org; | ||
|
Yoshihara, Eiji (Yoshihara, E) |
교신저자 |
Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA Harbor UCLA Med Ctr, Lundquist Inst Biomed Innovat, Torrance, CA 90509 USA Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA |
|
0000-0001-6324-6495 Yoshihara, Eiji |
[JCR상위 2.7] Estrogen-Related Receptor γ Maintains Pancreatic Acinar Cell Function and Identity by Regulating Cellular Metabolism | SCIE | 2.7 | GASTROENTEROLOGY & HEPATOLOGY | eiji.yoshihara@lundquist.org;evans@salk.edu;jmsuh@kaist.ac.kr; | |
|
Yu, Ruth T. (Yu, RT) |
Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA |
|
|
[JCR상위 2.7] Estrogen-Related Receptor γ Maintains Pancreatic Acinar Cell Function and Identity by Regulating Cellular Metabolism [JCR상위 0.7] Obesity alters pathology and treatment response in inflammatory disease |
SCIE | 0.7 |
GASTROENTEROLOGY & HEPATOLOGY MULTIDISCIPLINARY SCIENCES |
eiji.yoshihara@lundquist.org;evans@salk.edu;jmsuh@kaist.ac.kr; sagar.bapat@ucsf.edu;evans@salk.edu;yzheng@salk.edu;alexander.marson@ucsf.edu; |
||
|
Yung, Lotus (Yung, L) |
Daiichi Sankyo, Basking Ridge, NJ USA |
|
|
[JCR상위 2.7] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. [JCR상위 0.9] Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer |
SCIE | 0.9 |
ONCOLOGY MEDICINE, GENERAL & INTERNAL |
modis@mskcc.org; | ||
|
Zheng, Ye (Zheng, Y) |
Salk Inst Biol Studies, Nomis Labs Immunobiol & Microbial Pathogenesis, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA Salk Inst Biol Studies, NOMIS Ctr Immunobiol & Microbial Pathogenesis, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA |
G-4866-2015 Zheng, Ye |
|
[JCR상위 2.7] Estrogen-Related Receptor γ Maintains Pancreatic Acinar Cell Function and Identity by Regulating Cellular Metabolism [JCR상위 0.7] Obesity alters pathology and treatment response in inflammatory disease |
SCIE | 0.7 |
GASTROENTEROLOGY & HEPATOLOGY MULTIDISCIPLINARY SCIENCES |
eiji.yoshihara@lundquist.org;evans@salk.edu;jmsuh@kaist.ac.kr; sagar.bapat@ucsf.edu;evans@salk.edu;yzheng@salk.edu;alexander.marson@ucsf.edu; |
||
|
Chang, Joon Young (Chang, JY) |
Chungnam Natl Univ, Dept Med Sci, Daejeon, South Korea Chungnam Natl Univ, Sch Med, Res Ctr Endocrine & Metab Dis, 282 Munhwaro, Daejeon 35015, South Korea |
|
|
[JCR상위 2.8] Skeletal muscle mitoribosomal defects are linked to low bone mass caused by bone marrow inflammation in male mice | SCIE | 2.8 | GERIATRICS & GERONTOLOGY;MEDICINE, GENERAL & INTERNAL | jmpbooks@cnu.ac.kr; |
페이지 이동: